The critical Pas1 interval encompasses Bcat1, Lrmp, Casc1 (also known as Las1), Ghiso (also known as 4930469P12Rik), Kras2 and Lmna-rs1 (also known as 4933403M22Rik or Pas1c1) (ref. 6 ). Of these, only Kras2 is a known target of mutation in lung tumors 2, 3 , and mice expressing oncogenic Kras2 have a high incidence of early-onset lung cancer 7, 8 . Lung tumors from F1-hybrid mice showed a strong bias for Kras2 mutation involving the allele inherited from the more susceptible parent 9 , rendering Kras2 a candidate for Pas1. However, the possible mechanisms by which Kras2 may contribute to the effect of Pas1 remain unclear, causing some investigators to focus on other genes in the Pas1 region as primary candidates 10, 11 . Moreover, Pas1 was recently associated with susceptibility to lung inflammation 12 , raising the possibility that the major effect of Pas1 might be to control responses to the carcinogens used to induce lung tumorigenesis.
In the Kras2 LA2 model 7 of lung cancer, the Kras2 LA2 allele is inherited in a dormant form but becomes functionally activated by somatic recombination. Mice carrying Kras2 LA2 show complete penetrance for lung cancer, with tumors in other tissues occurring at very low frequencies 7 . The use of these mice removes the need for a chemical carcinogen and also fixes the origin of the mutant parental allele of Kras2. In interspecific crosses involving these mice, the mutant Kras2 allele is always present on the M. musculus parental chromosome, in contrast to crosses involving mice with two wild-type alleles, which are both potentially susceptible to carcinogen-induced mutation. We bred the Kras2 LA2 allele to a pure FVB/N strain background prior to carrying out crosses with SPRET/Ei resistant mice (see Methods). FVB/N mice are generally highly susceptible to epithelial tumor development 13 and carry the same Pas1 susceptibility haplotype as the 129/Sv strain 6 . SPRET/Ei mice carry dominant resistant alleles
Tumor number Tumor number for tumor development in multiple tissues 14 , and in particular carry a Pas1 resistance haplotype 5 . As expected, all Kras2 LA2 FVB/N mice developed multiple lung adenomas by 6 months of age. In contrast, F1 hybrids generated between Kras2 LA2 FVB/N and SPRET/Ei had relatively low tumor incidence and number at 6 months ( Fig. 1a) , and some animals survived well over one year without becoming moribund. We mated female FVBSPRETF1 hybrids with male Kras2 LA2 FVB/N mice to generate a large population of interspecific backcross mice. A total of 224 (FVBSPRETF1)FVBKras2 LA2 backcross mice were grown to age 6 months and then killed to assess tumor number. The distribution of tumor number was very wide (Fig. 1a) , in agreement with the observation that there are many lung tumor susceptibility and resistance loci 15, 16 . These animals were genotyped using markers on chromosome 6 to test for linkage to Pas1. We envisaged two possible outcomes: (i) if Kras2 is the Pas1 gene, there should be no linkage to the region, as every mouse carries the same parental mutant allele. This would be compatible with a mechanism in which selection for a more highly active or highly expressed Kras2 mutant allele in chemical carcinogenesis studies accounts completely for the effect of Pas1 (ref. 9). (ii) If Pas1 is a different gene(s) in the region, there should be linkage to distal chromosome 6, and the resistance allele should be inherited from the SPRET/Ei parent. This would be in agreement with the recent proposals that the major effect of Pas1 is mediated by Casc1 (ref. 10 ) and/or Lmna-rs1 (ref. 11). In fact, the results showed that neither of these hypotheses was correct. As shown in Table 1 , we detected strong linkage to the Pas1 region, but mice homozygous for the FVB/N haplotype developed significantly fewer tumors than the FVB/SPRET heterozygotes. The most susceptible mice carried one SPRET/Ei allele, rather than two FVB/N alleles, as would have been expected from previous work 17 .
To confirm previous results that SPRET/Ei mice are resistant at the Pas1 locus, 97 wildtype interspecific backcross mice ((MUS-SPRETF1)MUS; see Methods)) involving SPRET/Ei were subjected to chemical carcinogenesis using urethane. These MUS-SPRETF1 mice were clearly resistant to urethane-induced lung cancer (Fig. 1b) , and backcross mice treated with urethane showed a wide distribution of tumor numbers. Because mice of the FVB/N or NIH/Ola strains have not been used previously for lung chemical carcinogenesis, we carried out molecular analysis of tumors to identify Kras2 mutations. We found activating point mutations in 46 of 61 cases, and most of these were at codon 61 (Supplementary Table 1 online). Kras2 mutation frequency was similar in backcross animals derived from the FVB/N (30 of 38) or NIH/Ola (16 of 23) parents, in agreement with the observation that these closely related strains have the same haplotype at the Pas1 locus (see Methods). We detected significant linkage in the Pas1 region, with mice homozygous for M. musculus alleles developing significantly more tumors than heterozygous MUS/SPRET mice, confirming that the FVB/NIH Pas1 allele confers susceptibility and that of SPRET/Ei confers resistance to chemically induced lung tumors ( Table 1) . We also detected suggestive linkage at proximal chromosome 6, in the region of the pulmonary adenoma resistance 4 (Par4) Chemical carcinogenesis locus 18 . We also detected significant linkage at Par4 in the (FVBSPRETF1)FVBKras2 LA2 mice, and as with the chemical carcinogenesis approach, the FVB/N allele conferred relative resistance ( Table 1 ).
These data demonstrate that fixation of the parental origin of the mutant Kras2 allele leads to reversal of the resistance that is normally conferred by the SPRET/Ei allele at Pas1. The maintenance of directionality at Par4 in both crosses rules out the possibility of unforeseen artifacts in the model systems used here. The variance in lung tumor numbers accounted for by Pas1 in the chemical carcinogenesis (R 2 ¼ 10.2) and the Kras2 LA2 model (R 2 ¼ 11.7) was very similar, suggesting that most or all of the effect of Pas1 was reversed in these genetic crosses. Although specific cancer QTLs can confer either resistance or susceptibility depending on the tissue 19 , to our knowledge, this is the first report of a status switch involving the same allele at a cancer susceptibility locus by genetic manipulation of the target gene. The results demonstrate a highly context-dependent mechanism associated with Pas1 regulation of lung cancer susceptibility.
The most plausible explanation for the above results is that Pas1 is in fact Kras2, and that a delicate balance between the expression levels of the wild-type and oncogenic alleles controls predisposition to lung cancer development. The ratio of wild-type to mutant ras gene copy number has been shown to be an important factor in tumor initiation and progression [20] [21] [22] . Functional studies suggested that wild-type Ras can inhibit the effect of the corresponding oncogenic proteins 23, 24 , causing selection for loss of wild-type alleles during tumor development 21, 22 . Recent work demonstrated the ability of wild-type Kras2 to efficiently suppress the oncogenic activity of mutant Kras2 in a gene dosage-dependent manner 24 . These studies collectively suggested that susceptibility to lung carcinogenesis could be associated with the expression level of endogenous Kras2 alleles. Some limited data suggested higher levels of Kras2 expression in susceptible strains of mice 25 . We confirmed and extended this association using quantitative real-time PCR to accurately measure Kras2 expression in normal lungs of seven different mouse strains. Strains with a susceptible Pas1 haplotype had higher levels of Kras2 than those with a resistant haplotype (Fig. 2a) . The most susceptible A/J mice 2 had the highest level of Kras2 expression, while other susceptible strains, including FVB/N, NIH/Ola and 129/Sv, also expressed Kras2 at levels significantly higher than resistant strains (C57Bl/6, SPRET/Ei and SPRET/ Glasgow). The levels of Bcat1, Lmna-rs1, Casc1, Ghiso and Lrmp also varied (Fig. 2b-f ), but without any apparent correlation with lung cancer susceptibility.
The model that we believe can best explain results from both chemical carcinogenesis studies and the data from the Kras2 LA2 mouse is shown in Figure 3 . In traditional chemical carcinogenesis (Fig. 3a) , mice with two copies of the Pas1 susceptibility allele developed more tumors than those with the other possible genotypes, presumably because of the presence of two highly expressed Kras2 alleles, each of which is a target for mutation. When the initiating oncogenic mutation can occur on either of two alternative Kras2 alleles in the heterozygotes, fewer lung tumors develop because mutations involving the poorly expressed Kras2 allele (that is, SPRET/Ei) are selected against by the strong inhibitory activity of the highly expressed wild-type Kras2 (that is, FVB/N or NIH/Ola). Conversely, in the Kras2 LA2 model where the mutation is fixed on the parental FVB/N allele (Fig. 3b) , mice heterozygous at Pas1 are more susceptible to tumor formation because the poorly expressed wild-type Kras2 allele of SPRET/Ei is less efficient in suppression of the activity of the highly expressed mutant allele. Although we cannot rule out a role for coding polymorphisms in Lrmp, Ghiso, Casc1, or Lmna-rs1 at the Pas1 locus, it is difficult to reconcile the unexpected reversal of the effect on cancer susceptibility at Pas1 that would involve any of these genes. Notably, SPRET/Ei carries the 'resistance' polymorphism in the Casc1 gene 10 , in addition to a Kras2 allele that is poorly expressed. It can be concluded that the proposed resistance polymorphism in the Casc1 gene, and indeed candidate Pas1 resistance alleles of the other genes within the locus, are outweighed by the effects of the reduced expression level of the Kras2 gene from the SPRET/Ei parent, thus rendering Kras2 responsible for most, if not all, of the effect of Pas1 on lung cancer susceptibility. A prerequisite for the proposed model of Kras2 expression as a major determinant of lung cancer susceptibility is that one or more cis-acting polymorphisms should be responsible for the effect observed. If the expression of Kras2 was solely under the control of trans-acting factors (trans QTL) 26, 27 at different genomic locations, this would not be compatible with the model proposed. To examine these alternative possibilities, we generated an additional independent population of untreated, wild-type (FVBSPRETF1)FVB backcross mice, and measured the expression levels of Kras2 in the normal lungs of a total of 47 animals. Genotyping of the same mice at the Kras2 locus showed an association between Kras2 expression levels and Kras2/Pas1 genomic status. Mice homozygous for the FVB/N allele at Kras2/Pas1 had significantly higher average levels of Kras2 mRNA than FVB/SPRET heterozygous mice (P ¼ 0.033; Supplementary Fig. 1  online) , confirming the presence of a cis QTL that controls Kras2 expression levels. The mouse Kras2 genomic locus contains multiple polymorphisms among inbred mouse strains, and further detailed in vitro studies will be necessary identify the specific polymorphism(s) responsible for cis control of Kras2 expression. Nevertheless, the identification of a cis QTL for Kras2 expression provides strong support for the model presented in Figure 3 .
Association studies of human lung cancer identified suggestive linkage to chromosome 12p 28, 29 , in the region of the human Kras2 gene, but these findings remain controversial. Our results suggest the importance of simultaneous analysis of the somatic events in tumors in association studies of this kind. Only about 15-30% of human lung tumors carry Kras2 mutations, and although a highly expressed allele may confer susceptibility to tumors in which that particular allele is mutated, the same allele may confer resistance if the alternative allele undergoes mutation, or if the tumor carries no ras mutation at all. It will therefore be important to carry out similar association studies specifically on cases with tumors that have acquired somatic Kras2 mutations.
METHODS
Mouse breeding and lung tumorigenesis. The original Kras2 LA2 strain (a mixed C57Bl/6 and 129/Sv background) was bred with FVB/N mice, carrying the Kras2 LA2 allele through 13 generations. Interspecific backcross mice were generated by first breeding FVB/N with SPRET/Ei mice and then using the wild-type female FVBSPRETF1 animals to breed with male FVBKras2 LA2 mice.
All backcross animals positive for the Kras2 LA2 gene were maintained until 6 months of age, at which time they were sacrificed and their lung tissues fixed in 70% ethanol to facilitate tumor counting under a dissecting microscope.
Wild-type (FVBSPRETF1)FVB and (NIHSPRETF1)NIH backcross mice were generated similarly to above. FVB/N and NIH/Ola strains are very closely related 30 and have very similar levels of Kras2 expression (Fig. 2a) . Using a number of sequencing length polymorphisms (D6Int27, D6Int17, D6Mit109, D6Mit209 and D6Int14.1) around the Pas1 region and single nucleotide polymorphisms in Kras2 intronic sequences, we found FVB/N and NIH/Ola to be identical at these markers, indicating that they carry the same susceptible Pas1 haplotype. (FVBSPRETF1)FVB and (NIHSPRETF1)NIH mice were therefore treated in the analysis as a single population, referred to as (MUS-SPRETF1)MUS mice. These mice were treated with a single dose of urethane (in PBS; at 1 g/kg body mass) by intraperitoneal injection, and killed 20 weeks later for analysis of lung tissues as above.
All mouse experiments were approved by the University of California, San Francisco Laboratory Animal Resource Center.
Genotyping. Genomic DNA was extracted from tail clippings by conventional methods. We genotyped backcross mice using markers on chromosome 6 (Table 1) using conventional PCR. FVB/N and SPRET/Ei alleles of Kras2 were distinguished by a FokI digestion assay that targets the second intron of Kras2 (ref. 17) . Additional genotyping was performed by the Center for Inherited Disease Research (CIDR). A total of 224 (FVBSPRETF1)FVBKras2 LA2 mice were used in the analysis, but the genotyping assays failed in a very small number of cases. Statistical analyses were performed using the Mann-Whitney test as part of the SPSS package.
Gene expression studies. Lungs from untreated mice were immediately frozen in liquid nitrogen after sacrifice by cervical dislocation. RNA was extracted using Trizol reagent (Invitrogen) following the instructions of the manufacturer. Residual contaminating genomic DNA was removed by DNase treatment. TaqMan assays for gene expression analysis were purchased from Applied Biosystems (see below). The Gapdh housekeeping gene was used as an internal control (see Supplementary Table 2 online for oligonucleotide sequences).
Accession codes. Gene expression analysis (Applied Biosystems): Kras2 (Mm00517491_m1), Bcat1 (Mm00500289_m1), Casc1 (Mm01259185_m1), Ghiso (Mm01259203_m1), Lrmp (Mm00493168), and Lmna-rs1 (Mm00511959_m1).
URLs. Mouse Kras2 genomic locus: http://www.genenetwork.org/cgi-bin/beta/ snpBrowser.py.
Note: Supplementary information is available on the Nature Genetics website. 
